1. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT). Issue 3 (23rd February 2020) Authors: Dimopoulos, Meletios A.; Cavo, Michele; Mateos, Maria-Victoria; Facon, Thierry; Heeg, Bart; van Beekhuizen, Sophie; Gebregergish, Samron B.; Nair, Sandhya; Pisini, Marta; Lam, Annette; Slavcev, Mary Journal: Leukemia & lymphoma Issue: Volume 61:Issue 3(2020) Page Start: 714 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. (4th May 2021) Authors: Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C.; Leip, Eric; Viqueira, Andrea; Heeg, Bart Journal: Current medical research and opinion Issue: Volume 37:Number 5(2021) Page Start: 801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching. Issue 1 (7th November 2020) Authors: Moreau, Philippe; Hulin, Cyrille; Zweegman, Sonja; Hashim, Mahmoud; Hu, Yannan; Heeg, Bart; de Boer, Carla; Vanquickelberghe, Veronique; Kampfenkel, Tobias; He, Jianming; Lam, Annette; Cote, Sarah; Sonneveld, Pieter Journal: EJHaem Issue: Volume 2:Issue 1(2021) Page Start: 66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. (3rd May 2020) Authors: Stintzing, Sebastian; van Oostrum, Ilse; Pescott, Chris P.; Ronga, Philippe; Heeg, Bart; Heinemann, Volker Journal: Journal of medical economics Issue: Volume 23:Number 5(2020) Page Start: 448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. (2nd September 2019) Authors: Cortes, Jorge E.; Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C.; Crescenzo, Rocco J.; Su, Yun; Gambacorti-Passerini, Carlo; Heeg, Bart; Douglas Smith, B. Journal: Current medical research and opinion Issue: Volume 35:Number 9(2019) Page Start: 1615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Network meta‐interpolation: Effect modification adjustment in network meta‐analysis using subgroup analyses. (4th November 2022) Authors: Harari, Ofir; Soltanifar, Mohsen; Cappelleri, Joseph C.; Verhoek, Andre; Ouwens, Mario; Daly, Caitlin; Heeg, Bart Journal: Research synthesis methods Issue: Volume 14:Number 2(2023) Page Start: 211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PP113 Reimbursement Of Oncology Therapies With Limited Clinical Evidence In The Netherlands. (23rd December 2022) Authors: Smalbrugge, David; van Beekhuizen, Sophie; Heeg, Bart Journal: International journal of technology assessment in health care Issue: Volume 38(2022)Supplement 1 Page Start: S77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada. (1st January 2021) Authors: Hu, Yannan; Charaan, Majed; van Oostrum, Ilse; Heeg, Bart; Bell, Timothy Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations. (3rd March 2020) Authors: Gebregergish, Samron Brhane; Hashim, Mahmoud; Heeg, Bart; Wilke, Thomas; Rauland, Marco; Hostalek, Ulrike Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 20:Number 2(2020) Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Issue 3 (23rd February 2020) Authors: Mateos, Maria-Victoria; San-Miguel, Jesus; Goldschmidt, Hartmut; Sonneveld, Pieter; Dimopoulos, Meletios A.; Heeg, Bart; Hashim, Mahmoud; Deraedt, William; Hu, Peter; Lam, Annette; He, Jianming Journal: Leukemia & lymphoma Issue: Volume 61:Issue 3(2020) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗